Cargando…
Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice
In IPF, commencement of antifibrotic therapy in patients with preserved lung volume may increase the duration of therapy http://ow.ly/4HeM30lFS67
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Respiratory Society
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194204/ https://www.ncbi.nlm.nih.gov/pubmed/30364342 http://dx.doi.org/10.1183/23120541.00049-2018 |
| _version_ | 1783364191920324608 |
|---|---|
| author | Fletcher, Sophie V. Jones, Mark G. Renzoni, Elizabeth A. Parfrey, Helen Hoyles, Rachel K. Spinks, Katherine Kokosi, Maria Kwok, Apollinaris Warburton, Chris Titmuss, Vanessa Thillai, Muhunthan Simler, Nicola Maher, Toby M. Brereton, Christopher J. Chua, Felix Wells, Athol U. Richeldi, Luca Spencer, Lisa G. |
| author_facet | Fletcher, Sophie V. Jones, Mark G. Renzoni, Elizabeth A. Parfrey, Helen Hoyles, Rachel K. Spinks, Katherine Kokosi, Maria Kwok, Apollinaris Warburton, Chris Titmuss, Vanessa Thillai, Muhunthan Simler, Nicola Maher, Toby M. Brereton, Christopher J. Chua, Felix Wells, Athol U. Richeldi, Luca Spencer, Lisa G. |
| author_sort | Fletcher, Sophie V. |
| collection | PubMed |
| description | In IPF, commencement of antifibrotic therapy in patients with preserved lung volume may increase the duration of therapy http://ow.ly/4HeM30lFS67 |
| format | Online Article Text |
| id | pubmed-6194204 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | European Respiratory Society |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-61942042018-10-24 Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice Fletcher, Sophie V. Jones, Mark G. Renzoni, Elizabeth A. Parfrey, Helen Hoyles, Rachel K. Spinks, Katherine Kokosi, Maria Kwok, Apollinaris Warburton, Chris Titmuss, Vanessa Thillai, Muhunthan Simler, Nicola Maher, Toby M. Brereton, Christopher J. Chua, Felix Wells, Athol U. Richeldi, Luca Spencer, Lisa G. ERJ Open Res Original Research Letters In IPF, commencement of antifibrotic therapy in patients with preserved lung volume may increase the duration of therapy http://ow.ly/4HeM30lFS67 European Respiratory Society 2018-10-19 /pmc/articles/PMC6194204/ /pubmed/30364342 http://dx.doi.org/10.1183/23120541.00049-2018 Text en Copyright ©ERS 2018 http://creativecommons.org/licenses/by-nc/4.0/ This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. |
| spellingShingle | Original Research Letters Fletcher, Sophie V. Jones, Mark G. Renzoni, Elizabeth A. Parfrey, Helen Hoyles, Rachel K. Spinks, Katherine Kokosi, Maria Kwok, Apollinaris Warburton, Chris Titmuss, Vanessa Thillai, Muhunthan Simler, Nicola Maher, Toby M. Brereton, Christopher J. Chua, Felix Wells, Athol U. Richeldi, Luca Spencer, Lisa G. Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice |
| title | Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice |
| title_full | Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice |
| title_fullStr | Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice |
| title_full_unstemmed | Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice |
| title_short | Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice |
| title_sort | safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine uk clinical practice |
| topic | Original Research Letters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194204/ https://www.ncbi.nlm.nih.gov/pubmed/30364342 http://dx.doi.org/10.1183/23120541.00049-2018 |
| work_keys_str_mv | AT fletchersophiev safetyandtolerabilityofnintedanibforthetreatmentofidiopathicpulmonaryfibrosisinroutineukclinicalpractice AT jonesmarkg safetyandtolerabilityofnintedanibforthetreatmentofidiopathicpulmonaryfibrosisinroutineukclinicalpractice AT renzonielizabetha safetyandtolerabilityofnintedanibforthetreatmentofidiopathicpulmonaryfibrosisinroutineukclinicalpractice AT parfreyhelen safetyandtolerabilityofnintedanibforthetreatmentofidiopathicpulmonaryfibrosisinroutineukclinicalpractice AT hoylesrachelk safetyandtolerabilityofnintedanibforthetreatmentofidiopathicpulmonaryfibrosisinroutineukclinicalpractice AT spinkskatherine safetyandtolerabilityofnintedanibforthetreatmentofidiopathicpulmonaryfibrosisinroutineukclinicalpractice AT kokosimaria safetyandtolerabilityofnintedanibforthetreatmentofidiopathicpulmonaryfibrosisinroutineukclinicalpractice AT kwokapollinaris safetyandtolerabilityofnintedanibforthetreatmentofidiopathicpulmonaryfibrosisinroutineukclinicalpractice AT warburtonchris safetyandtolerabilityofnintedanibforthetreatmentofidiopathicpulmonaryfibrosisinroutineukclinicalpractice AT titmussvanessa safetyandtolerabilityofnintedanibforthetreatmentofidiopathicpulmonaryfibrosisinroutineukclinicalpractice AT thillaimuhunthan safetyandtolerabilityofnintedanibforthetreatmentofidiopathicpulmonaryfibrosisinroutineukclinicalpractice AT simlernicola safetyandtolerabilityofnintedanibforthetreatmentofidiopathicpulmonaryfibrosisinroutineukclinicalpractice AT mahertobym safetyandtolerabilityofnintedanibforthetreatmentofidiopathicpulmonaryfibrosisinroutineukclinicalpractice AT breretonchristopherj safetyandtolerabilityofnintedanibforthetreatmentofidiopathicpulmonaryfibrosisinroutineukclinicalpractice AT chuafelix safetyandtolerabilityofnintedanibforthetreatmentofidiopathicpulmonaryfibrosisinroutineukclinicalpractice AT wellsatholu safetyandtolerabilityofnintedanibforthetreatmentofidiopathicpulmonaryfibrosisinroutineukclinicalpractice AT richeldiluca safetyandtolerabilityofnintedanibforthetreatmentofidiopathicpulmonaryfibrosisinroutineukclinicalpractice AT spencerlisag safetyandtolerabilityofnintedanibforthetreatmentofidiopathicpulmonaryfibrosisinroutineukclinicalpractice |